BioNTech SE
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ugur Sahin
- Full Time Employees
- 6,772
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- An der Goldgrube 12 Mainz Germany 55131
- IPO Date
- Oct 10, 2019
- CIK
- 0001776985
- Website
- biontech.de
- Similar Companies
- Business
- BioNTech SE (BNTX) is a biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. The company offers a broad portfolio of products and services, including mRNA-based therapeutics and vaccines such as Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer; individualized neoantigen-specific immunotherapies under the BioNTech's FixVac and iNeST platforms; antibody-drug conjugates; small molecule immunomodulators; and cell therapies targeting solid tumors and hematological malignancies; as well as oncology pipeline candidates like BNT327 (a PD-L1/VEGF bispecific antibody) and BNT116 (a next-generation FixVac for lung cancer). BioNTech operates primarily in the biopharmaceutical industry, serving global patient populations through clinical trials, regulatory approvals, and commercial distribution in over 30 countries across North America, Europe, Asia-Pacific, and emerging markets. Founded in 2008 and headquartered in Mainz, Germany, the company maintains subsidiaries worldwide, including in the United States, the United Kingdom, and China, with no parent company. Recent developments include the European Medicines Agency's approval in 2024 for BNT116 as the first mRNA-based lung cancer therapeutic; a multi-billion-dollar expansion of its manufacturing facilities in Rwanda and Australia announced in early 2025 to enhance global vaccine production capacity; deepened strategic alliances with Pfizer for next-generation COVID-19 vaccines and with Genentech for bispecific antibody development; and a $760 million funding round in late 2024 to advance its oncology pipeline amid robust Phase 3 trial progress.
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO
Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally
BioNTech Announces New ADS Repurchase Program
BioNTech Q3 Earnings Review: Getting Into The Weeds With Bewildering Oncology Plans
Germany says vaccine supply secure despite BioNTech production loss
BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript
BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape
BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push
BioNTech to close sites in Germany, Singapore affecting 1,860 staff
BioNTech Announces First Quarter 2026 Financial Results and Corporate Update
Stock Market Today (LIVE): Tesla Beats but Shares Fall on $25 Billion Capex Surprise as Iran Breakdown Sends Oil Back Above $103
BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains?
Two experimental drugs showed striking early results against pancreatic cancer
BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
2 Healthcare Stocks to Buy and 1 to Approach With Caution